Navigation Links
Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
Date:5/29/2012

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final safety and pharmacokinetic data expected in the first half of 2013.

"We are very pleased to see the excitement surrounding our initial clinical trial of ME-344, with the first cohort of patients now well underway just a month after our Investigational New Drug application was approved by the FDA," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "ME-344 is a novel compound that showed compelling anti-tumor activity in pre-clinical studies. Now we look forward to gathering valuable clinical data in the months ahead, all of which will help to optimize the design of our Phase II efficacy studies."

The Phase I clinical trial is evaluating the safety and tolerability of intravenous ME-344 in escalating dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg. In addition, the trial is designed to characterize the pharmacokinetic profile of ME-344 and describe any preliminary clinical anti-tumor activity observed. Patients in the trial are administered intravenous infusions of ME-344 once weekly for three weeks and, after safety assessment, may continue weekly dosing if a clinical benefit is determined.

The open-label trial is being conducted in collaboration with the Sarah Cannon Research Institute at three sites: Florida Cancer Specialists in Sarasota, University of Oklahoma in Oklahoma City and Tennessee Oncology in Nashville. Additional information
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
3. Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
4. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
5. Marshall Edwards Announces Rights Offering to Stockholders
6. Marshall Edwards Adds $2 Million in Private Placement
7. Marshall Edwards Announces $2 Million Private Placement
8. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
9. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. ... dedicated to delivering high quality and novel medicines to ... Chief Executive Officer Mark Baum will be ... Alpha Select Conference in New York City.  Mr. Baum ... Go Dropless™ campaign in ophthalmology. The presentation is scheduled ...
(Date:9/16/2014)... , Sept. 16, 2014  Wearable sports and ... in less than two years, producing a massive ... A huge opportunity exists for leveraging this data ... http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable analytics platform ... years of clinical research linking activity and health ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
... III Study Provides Further Evidence of,the Significant ... Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June 6, ... multinational phase III Actemra,(tocilizumab) study, successfully reached ... proportion of patients treated with Actemra,in combination ...
... Topical Therapy Reduces TNF-alpha Production Through Inhibition,of ... 2007 /PRNewswire/ -- Anacor,Pharmaceuticals, a privately held ... placebo-controlled Phase 1 trial of,AN2728, a first-in-class ... psoriasis. The trial showed AN2728 to be,well-tolerated, ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:9/16/2014)... Seven heroes who have dramatically improved the ... in New York City on November 6 by World ... recognition and funding program that honors individuals serving vulnerable ... the “Nobel Prize for Child Advocates,” this year’s selection ... benefit children in countries around the world dealing with ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in the ... association that works to find ways to prevent and cure ... affects the functioning of the heart and can lead to ... years. , What:, Colorado PH in the Park 2014 ...
(Date:9/16/2014)... 2014 As part of its Latinos ... Citizens (LULAC) will host the second annual health festival ... feature free health screenings for osteoporosis, HIV, and high ... and cholesterol levels as well as bone marrow typing. ... under 6 years old , The event will also ...
(Date:9/16/2014)... women older than 70 in national breast cancer screening ... forms of the disease, a new study finds. ... in older women being overdiagnosed and overtreated, the Dutch ... women for breast cancer should be made on a ... screening, the decision to participate in the screening program ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... cancer survivors are alive today, compared to just 3 ... reported Tuesday. These individuals amount to 4 percent ... childhood cancer, according to the association,s annual progress report. ... treatment of cancer and details some of the challenges ...
Breaking Medicine News(10 mins):Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Some Benefits of Screening Elderly Women for Breast Cancer Questioned 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... ... in Financial Journalism Award from the New York State Society of Certified Public Accountants (NYSSCPA). ... New York, NY (PRWEB) ... CFO magazine , won an Excellence in Financial Journalism Award from the New York State ...
... ... leading provider of Semantic Web infrastructure technologies announced today that it has entered ... ... 2010 -- Intellidimension, Inc. a leading provider of Semantic Web infrastructure technologies announced ...
... ... response services and solutions, has introduced iCAN, a feature-rich, streamlined approach to automated telephony services. ... up fees and extremely quick turnaround times to start up. , ... Buffalo, New York (Vocus) April 6, 2010 -- ...
... ... Many important secrets have been kept from the public about ... unknown players in the health care reformation debacle. Author of "The ... of the insights contained in his new work, now available on ...
... report disabilities related to mobility increased significantly from 1997 to ... found among Americans ages 65 and over, according to a ... Michigan. Researchers found a rise in the proportion of ... the need for help in daily personal care activities such ...
... of Wisconsin-Madison, one of the most powerful magnetic ... pregnant patients for rare but very serious fetal ... The Medical College of Wisconsin, Milwaukee; Children,s Hospital ... the ultrasensitive detector measures magnetic signals coming from ...
Cached Medicine News:Health News:CFO magazine Wins Excellence in Financial Journalism Award 2Health News:Intellidimension Announces Semantic Web Technology Partnership with Matrikon 2Health News:Intellidimension Announces Semantic Web Technology Partnership with Matrikon 3Health News:IVR Technology Group Announces iCANsm Services 2Health News:Health Care Reform's Hidden Racket Exposed 2Health News:Health Care Reform's Hidden Racket Exposed 3Health News:Health Care Reform's Hidden Racket Exposed 4Health News:Middle-aged Americans reporting more mobility related disabilities, study finds 2Health News:Middle-aged Americans reporting more mobility related disabilities, study finds 3Health News:Ultrasensitive detector pinpoints big problem in tiny fetal heart 2Health News:Ultrasensitive detector pinpoints big problem in tiny fetal heart 3Health News:Ultrasensitive detector pinpoints big problem in tiny fetal heart 4
... Hospitals, correctional facilities, recreational venues ... wristbands to provide automated data capture ... reducing costly and dangerous errors. RFID ... admissions wristbands at entertainment venues as ...
Computer-generated Smart CompuBand can be simultaneously printed with bar code information and programmed with RFID information...
... The optional Kisses component ... designed to assist nursing staff ... mothers while in the hospital. ... you have an easy, effective ...
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
Medicine Products: